← Back to Clinical Trials
Recruiting NCT00470327

NCT00470327 A Study of the Natural Progression of Interstitial Lung Disease (ILD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00470327
Status Recruiting
Phase
Sponsor University of Chicago
Condition Interstitial Lung Diseases
Study Type OBSERVATIONAL
Enrollment 4,000 participants
Start Date 2005-09
Primary Completion 2030-12

Trial Parameters

Condition Interstitial Lung Diseases
Sponsor University of Chicago
Study Type OBSERVATIONAL
Phase N/A
Enrollment 4,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2005-09
Completion 2030-12

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.

Eligibility Criteria

Inclusion Criteria: * Interstitial lung disease Exclusion Criteria: * Does not have Interstitial lung disease

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology